YARAL Pharma Inc., launched in 2022, is the U.S. generics subsidiary of IBSA (Institut Biochimique SA), a multinational pharmaceutical company headquartered in Lugano, Switzerland. Built on IBSA’s commitment to “drugs in the best form,” YARAL delivers high-quality, affordable, authorized and complex generic medicines across key therapeutic areas—including endocrinology and pain and inflammation—while ensuring continuity of supply and patient-focused innovation.
Created to expand IBSA’s presence in the U.S. market, YARAL combines global manufacturing excellence with a customer-first approach. Since its launch, the company has quickly become one of IBSA’s top-performing subsidiaries, recognized for its consistent product quality, reliability of supply, and responsive service.
YARAL’s portfolio focuses on high-value, differentiated generics—including topical and transdermal patches and softgel technologies—that meet real needs in today’s pharmacy practice. Guided by quality, reliability, and innovation, YARAL is helping pharmacists provide patients with trusted treatment options across multiple therapeutic areas.